A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Idasanutlin (Primary)
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Roche
- 13 Oct 2017 Planned End Date changed from 2 Jul 2020 to 15 Jul 2020.
- 26 Sep 2017 Planned initiation date changed from 23 Sep 2017 to 6 Oct 2017.
- 22 Sep 2017 New trial record